•  

Posts Tagged: preclinical models

MaRS Innovation Forms Strategic Drug-Development Partnership with NovoTek Therapeutics Inc. in China

MaRS Innovation (MI), The Hospital for Sick Children (SickKids) and NovoTek Therapeutics Inc. (NovoTek)  have announced a strategic partnership to co‐develop, and bring to the Chinese market, a novel therapeutic cream aimed at reducing scar formation post surgery. This project was covered in The Globe and Mail on May 7, 2012. (more…) Read more

CAMH researcher’s leading-edge therapy targets brain chemistry of addiction

CAMH and MaRS Innovation partner on innovative approach to nicotine addiction TORONTO (Dec. 17, 2009) — Grappling with nicotine addiction is never easy, but a new drug therapy – developed by Dr. Fang Liu at the Centre for Addiction and Mental Health (CAMH) – brings promise to one of our great public health challenges. The experimental medication in development at Dr. Liu’s lab targets the brain chemistry associated with addiction by disrupting a specific receptor-receptor interaction. Proof-of-concept data demonstrate that this therapy decreases addictive ... Read more
Page 2 of 212